Involved 1195 patients in thirteen countries.

The study, which is the first phase 3 trial showing a significant survival benefit for a drug which works in this manner, involved 1195 patients in thirteen countries, and compared the consequences of prescribing abiraterone and the steroid prednisone, which combats a few of the side effects of prostate malignancy treatment, with a predisnone plus placebo. The trial participants had all undergone at least one earlier round of chemotherapy with another medication, docetaxel, which hadn’t halted the progression of their cancers drug information .8 months, in comparison to 11.2 months for those given a placebo. Related StoriesNew antenna-like gadget makes breast cancer medical procedures easier for surgeonsCrucial change in single DNA bottom predisposes children to intense form of cancerNew results reveal association between colorectal cancers and melanoma medication treatmentFor patients with metastatic prostate tumor, the average overall survival time for patients who’ve undergone chemotherapy is consistently significantly less than two years, therefore the increased survival time offered by abiraterone acetate you could end up substantially improved potential customers for individuals whose prostate cancer continues to progress after preliminary treatment with docetaxel.